Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Fig 5 - by Fatemeh Mohammadkhani (15927311)

Subjects:

pGab1 levels decreased over time in HCV-infected Huh7.5.1 cells. by Da-eun Nam (18927946)

Mean observer DCCR (%) and DDR (%) at C5-6 in neutral, flexed and extended neck positions in horses that were not operated (n = 16) versus operated (n = 6) at this site. by Devon England (21262225)

Mean observer DCCR (%) and DDR (%) at C4-5 in neutral, flexed and extended neck positions in horses that were not operated (n = 10) versus operated (n = 12) at this site. by Devon England (21262225)

Spatial information of excitatory neurons in APP/PS1 mice are decreased in dCA1 and vCA1. by Udaysankar Chockanathan (18510288)

“…<p>(A) In dCA1, spatial information was decreased in APP/PS1 mice relative to C57BL/6 controls (mean ± std: C57BL/6 = 0.134 ± 0.050, APP/PS1 = 0.132 ± 0.054, p < 0.01, two-sided Wilcoxon rank-sum test, n_C57BL/6 = 229 units from 5 recording sessions, n_APP/PS1 = 124 units from 4 recording sessions). …”

Image_2_Decreased Colonic Guanylin/Uroguanylin Expression and Dried Stool Property in Mice With Social Defeat Stress.tif by Nobuhiko Ebisutani (9764468)

“…A murine model of chronic social defeat stress (CSDS) was established by exposing a C57BL/6N intruder mouse to a CD-1 aggressor mouse for 3–5 min. …”

The numbers of parasite cysts in the brain decrease and the sizes increase as <i>Toxoplasma gondii</i> infection progresses in mice C57BL/6. by Leda Castaño Barrios (8524317)

ST2-104 decreases the Aβ_25-35-mediated increase in intracellular Ca²⁺. by Yingshi Ji (9013004)